AGR2 and pancreatic ductal adenocarcinoma: Zhang and colleagues designed an anti-AGR2 hexapeptide, NTAIYY, to target pancreatic ductal adenocarcinoma (PDAC) by competitively disrupting the AGR2-RNA polymerase II (RNAPII) complex [140].